伊普诺康品牌怎么样申请店铺

我要投票

伊普诺康在医疗器械行业中的票数：618 更新时间：2026-01-07

伊普诺康是哪个国家的品牌？「伊普诺康」是安徽伊普诺康生物技术股份有限公司旗下著名品牌。该品牌发源于安徽省合肥市，由创始人蔡晓辉在2012-03-06期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力伊普诺康品牌出海！将品牌入驻外推网，定制伊普诺康品牌推广信息，可以显著提高伊普诺康产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

【伊普诺康】是体外诊断行业内一家集研发、生产、销售和医学检验服务为一体的技术企业。公司创立之初，就确立了“以用户实际需求为导向”的产品理念。公司建立了新产品立项体系和完善的产品质量控制体系。

为切实贯彻公司产品理念，公司研发中心依托研发人才，搭建了包括常规生化试剂研发平台、免疫增强比浊试剂研发平台、特定蛋白分析仪及其试剂研发平台、尿生化试剂研发平台在内的多个研发平台；组建了系统参考部进行溯源研究，并报名参加IFCC举办的RELA测试，提升产品质量和溯源能力；成立了关键原材料研发中心，从源头把好质量关。

公司现有注册生化试剂产品近100项，涵盖肝功能、肾功能、心肌标志物、血脂、糖代谢、特种蛋白、肿瘤等品类，其中特色项目20余项，如小而密低密度脂蛋白胆固醇（sdLDL-C）、补体C1q、血清淀粉样蛋白A（SAA）、25羟基维生素D（25-OHD）、脂联素（ADP）、特异性生长因子（TSGF）、甘胆酸（CG）、IV型胶原蛋白（COL IV）等，此外，在注册产品达数十项。

公司自主研发的特定蛋白分析仪（梦T200 Plus）将于2019年上市，该特定蛋白分析仪能有效满足各级医院的个性化需求。该产品的成功推出，标志着伊普诺康已由过去单纯的试剂生产厂家发展为试剂和仪器配套生产的综合性生产企业。

“行远必自逊，追求无止境”。2016年2月，公司完成“新三板”挂牌（股票代码：835852），并与多家投资机构建立了战略合作关系，为公司的发展不断注入新的动力。

[iprnocon] is a technology enterprise integrating R & D, production, sales and medical testing services in the field of in vitro diagnosis. At the beginning of its establishment, the company established the product concept of "taking the actual needs of users as the guide". The company has established a new product project approval system and a perfect product quality control system. In order to effectively implement the company's product concept, the R & D center of the company has built a number of R & D platforms, including the R & D platform of conventional biochemical reagents, the R & D platform of immune enhancement turbidimetric reagents, the R & D platform of specific protein analyzer and its reagents, and the R & D platform of urine biochemical reagents, relying on R & D talents; established a system reference department for traceability research, and signed up to participate in the rela test held by IFCC Try to improve the product quality and traceability; set up the key raw material R & D center to control the quality from the source. The company has nearly 100 registered biochemical reagent products, covering liver function, kidney function, cardiac muscle marker, blood lipid, sugar metabolism, special protein, tumor and other categories, including more than 20 featured items, such as small and dense low-density lipoprotein cholesterol (sdldl-c), complement C1q, serum amyloid A (SAA), 25 hydroxyvitamin D (25-OHD), adiponectin (ADP), and specific growth Factor (TSGF), glycocholic acid (CG), collagen IV (coliv), etc. in addition, there are dozens of registered products. The company's self-developed specific protein analyzer (dreamt200plus) will be launched in 2019, which can effectively meet the personalized needs of hospitals at all levels. The successful launch of this product marks that iprnocon has developed from a simple reagent manufacturer to a comprehensive manufacturer of reagents and instruments. "If you go far, you will be inferior to yourself, and you will pursue endlessly.". In February 2016, the company completed the listing of the "new third board" (Stock Code: 835852), and established strategic cooperation relations with a number of investment institutions, which continuously injected new impetus into the development of the company.

本文链接： https://brand.waitui.com/39e768d86.html 联系电话：请联系客服添加联系邮箱：请联系客服添加